Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Alcohol ; 102: 59-65, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35569673

RESUMEN

Evidence suggests that phenobarbital can be used to treat alcohol withdrawal syndrome as monotherapy; however, the therapeutic cornerstone remains benzodiazepines. To date, studies comparing the two treatment modalities in the emergency department (ED) are few. We sought to determine whether phenobarbital versus benzodiazepine monotherapy impacts ED length of stay and need for admission among adult presentations at a single regional hospital. In June 2019, a treatment algorithm offering both phenobarbital and diazepam pathways was introduced at the Battlefords Union Hospital ED, an 11-bed unit treating 27 000 patients annually in North Battleford, Saskatchewan, Canada. A subsequent retrospective observational study evaluated all adult alcohol withdrawal syndrome presentations between June 2019 and January 2021. Medical records were reviewed for visit date, age, sex, comorbidities, psychosocial factors, Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores, secondary diagnoses, time of day, protocol adherence, attending physician, length of stay, disposition, and ED return. Descriptive statistics, log-rank testing, simple regression, and multiple regression were used in analysis. Of the 184 presentations, 30.4% were treated with phenobarbital. Median length of stay for phenobarbital versus benzodiazepine therapy was 4.4 h and 4.4 h, respectively (p = 0.21). Of the phenobarbital presentations, 9.4% were hospitalized versus 17.1% of the benzodiazepine presentations (p = 0.20). When adjusted for confounders, phenobarbital-treated presentations were 71.3% less likely to be admitted (p = 0.03). This research suggests that phenobarbital performs similarly to benzodiazepines regarding alcohol withdrawal ED length of stay and may result in reduced hospitalizations.


Asunto(s)
Alcoholismo , Síndrome de Abstinencia a Sustancias , Adulto , Alcoholismo/tratamiento farmacológico , Alcoholismo/epidemiología , Benzodiazepinas/uso terapéutico , Canadá/epidemiología , Servicio de Urgencia en Hospital , Humanos , Tiempo de Internación , Fenobarbital/uso terapéutico , Estudios Retrospectivos , Síndrome de Abstinencia a Sustancias/diagnóstico , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Síndrome de Abstinencia a Sustancias/epidemiología
2.
3.
Gynecol Oncol ; 90(1): 200-3, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12821365

RESUMEN

BACKGROUND: While acute gastric dilation is a postoperative complication familiar to most surgeons, massive dilatation with necrosis and rupture is a very rare event. We performed a computer search in the MEDLINE database for the years 1966-2001 for articles published in any language using the key words gastric dilation, gastric necrosis, intestinal obstruction, and gynecologic surgery. Our search yielded no reports of massive gastric dilation and ischemic necrosis from a small bowel obstruction following gynecologic surgery. CASE: A 76-year-old woman developed massive gastric dilatation with ischemic necrosis associated with small bowel obstruction following gynecologic surgery for benign disease. CONCLUSION: Gynecologists should be aware of the entity. Early diagnosis and treatment are essential to minimize morbidity and mortality.


Asunto(s)
Dilatación Gástrica/complicaciones , Procedimientos Quirúrgicos Ginecológicos/efectos adversos , Obstrucción Intestinal/complicaciones , Estómago/patología , Anciano , Femenino , Dilatación Gástrica/patología , Humanos , Necrosis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA